-
公开(公告)号：US20160340336A1
公开(公告)日：2016-11-24
申请号：US15158174
申请日：2016-05-18
Applicant: AMGEN INC.
Inventor： Ning Chen , Xiaoqi Chen , Yinhong Chen , Alan C. Cheng , Richard V. Connors , Jeffrey Deignan , Paul John Dransfield , Xiaohui Du , Zice Fu , Julie Anne Heath , Daniel B. Horne , Jonathan Houze , Matthew R. Kaller , Aarif Yusuf Khakoo , David John Kopecky , Su-Jen Lai , Zhihua Ma , Lawrence R. McGee , Julio C. Medina , Jeffrey T. Mihalic , Nobuko Nishimura , Steven H. Olson , Vatee Pattaropong , Gayathri Swaminath , Xiaodong Wang , Kevin Yang , Wen-Chen Yeh , Mikkel V. Debenedetto , Robert P. Farrell , Simon J. Hedley , Ted C. Judd , Frank Kayser
IPC: C07D401/14 , C07D213/82 , C07D241/24 , C07D239/30 , C07D239/26 , C07D401/04 , A61K31/4439 , A61K31/506 , C07D413/14 , C07B59/00 , A61K31/497 , A61K31/513 , C07D471/04 , A61K31/444 , C07D417/14 , C07B57/00 , C07D405/14 , A61K31/501 , C07D249/08 , C07D241/12 , C07D213/71 , C07D211/54 , A61K45/06
CPC classification number: A61K31/506 , A61K31/437 , A61K31/4439 , A61K31/444 , A61K31/497 , A61K31/501 , A61K31/513 , A61K31/695 , A61K45/06 , C07B57/00 , C07B59/002 , C07B2200/05 , C07B2200/07 , C07C311/13 , C07D211/54 , C07D213/61 , C07D213/71 , C07D213/82 , C07D239/26 , C07D239/30 , C07D239/34 , C07D241/12 , C07D241/18 , C07D241/24 , C07D249/08 , C07D295/16 , C07D401/04 , C07D401/12 , C07D401/14 , C07D405/14 , C07D413/04 , C07D413/14 , C07D417/14 , C07D471/04 , C07F7/08
Abstract: Compounds of Formula I and Formula II, pharmaceutically acceptable salt thereof, stereoisomers of any of the foregoing, or mixtures thereof are agonists of the APJ Receptor and have use in treating cardiovascular and other conditions. Compounds of Formula I and Formula II have the following structures: where the definitions of the variables are provided herein.
Abstract translation: 其中在这里提供变量的定义。
-
22.发明授权Fused pyridine, pyrimidine and triazine compounds as cell cycle inhibitors 有权融合的吡啶，嘧啶和三嗪化合物作为细胞周期抑制剂公开(公告)号：US08980903B2
公开(公告)日：2015-03-17
申请号：US14453842
申请日：2014-08-07
Applicant: Amgen Inc.
Inventor： Richard V. Connors , Kang Dai , John Eksterowicz , Pingchen Fan , Benjamin Fisher , Jiasheng Fu , Kexue Li , Zhihong Li , Lawrence R. McGee , Rajiv Sharma , Xiaodong Wang , Dustin L. McMinn , Jeffrey T. Mihalic , Jeffrey Deignan
IPC: C07D498/04 , C07D491/147 , C07D471/14 , C07D471/04 , C07D487/14 , C07D491/107 , C07D498/10
CPC classification number: C07D471/14 , A61K31/519 , A61K31/5377 , A61K31/5386 , C07D403/14 , C07D413/14 , C07D417/14 , C07D471/04 , C07D487/04 , C07D487/14 , C07D491/107 , C07D491/147 , C07D498/04 , C07D498/10 , C07D513/14
Abstract: Compounds, pharmaceutical compositions and methods are provided that are useful in the treatment of CDK4-mediated disorders, such as cancer. The subject compounds are fused pyridine, pyrimide and triazine derivatives.
Abstract translation: 提供了可用于治疗CDK4介导的疾病如癌症的化合物，药物组合物和方法。 本发明化合物是吡啶，吡嗪酰亚胺和三嗪衍生物。
-
公开(公告)号：US20140011796A1
公开(公告)日：2014-01-09
申请号：US14025688
申请日：2013-09-12
Applicant: AMGEN INC.
Inventor： Michael David BARTBERGER , Ana Gonzalez Buenrostro , Hilary Plake Beck , Xiaoqi Chen , Richard Victor Connors , Jeffrey Deignan , Jason Duquette , John Eksterwicz , Benjamin Fisher , Brian Matthew Fox , Jiasheng Fu , Zice Fu , Felix Gonzalez Lopez De Turiso , Michael William Gribble , Dann James Gustin , Julie Anne Heath , Xin Huang , Xianyun Jiao , Michael Johnson , Frank Kayser , David John Kopecky , Sujen Lai , Yihong Li , Zhihong Li , Jiwen Liu , Jonathan Dante Low , Brian Stuart Lucas , Zhihua Ma , Lawrence R. McGee , Joel McIntosh , Dustin McMinn , Julio Cesar Medina , Jeffrey Thomas Mihalic , Steven Howard Olson , Yosup Rew , Philip Marley Roveto , Daqing Sun , Xiaodong Wang , Yingcai Wang , Xuelei Yan , Ming Yu , Jiang Zhu
IPC: C07D211/76 , C07D417/12 , C07D413/06 , C07D471/10 , C07D409/04 , C07D401/04 , C07D279/02 , C07D491/08 , C07D498/08 , C07D417/14 , C07D491/153 , C07D417/06 , C07D401/06 , C07D405/04
CPC classification number: C07D211/76 , C07D221/20 , C07D279/02 , C07D401/04 , C07D401/06 , C07D401/12 , C07D405/04 , C07D405/12 , C07D407/04 , C07D407/06 , C07D409/04 , C07D409/12 , C07D413/06 , C07D417/06 , C07D417/12 , C07D417/14 , C07D471/10 , C07D491/08 , C07D491/153 , C07D498/08 , C07D498/14 , C07D498/20
Abstract: The present invention provides MDM2 inhibitor compounds of Formula I, wherein the variables are defined above, which compounds are useful as therapeutic agents, particularly for the treatment of cancers. The present invention also relates to pharmaceutical compositions that contain an MDM2 inhibitor.
-
-
Search Results
23
records
(took 0.039 seconds)
